- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03900273
Development of Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD)
Development of Novel Measures of Cognition and Function for Alzheimer's Disease Prevention Trials
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Terry E. Goldberg, Ph.D.
- Phone Number: 646-774-5215
- Email: teg2117@cumc.columbia.edu
Study Contact Backup
- Name: Davangere P. Devanand, M.D.
- Phone Number: 646-774-8658
- Email: dpd3@cumc.columbia.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
New York
-
Manhasset, New York, United States, 11030
- The Feinstein Institute for Medical Research
-
New York, New York, United States, 11032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- English speaking participants, ages 60-85 years
- MMSE score of 24 or greater
- Logical Memory II score of 9 or greater for subjects with 16 or more years of education, 5 or more for subjects with 8-15 years of education, and 3 or greater for subjects with 0-7 years of education
- Presence of subjective memory complaints not exclusionary
- A family member or other individual who is in contact with the subject and consents to serve as informant during the study.
Exclusion Criteria:
- Diagnosis of stroke or excessive risk of CVD
- Neurologic disease including movement disorders, MS, epilepsy, and TBI (with greater than 15 min loss of consciousness)
- Untreated diabetes
- Current DSM-5 Axis I psychiatric diagnosis of schizophrenia schizoaffective disorder or bipolar disorder; current major depression as determined by a Geriatric Depression Scale score of greater than 5. Current alcohol or substance use disorder
- Active treatment of cancer
- MMSE score below 24 and Logical Memory below 9 for subjects with 16 or more years of education, 5 for subjects with 8-15 years of education, and 3 for subjects with 0-7 years of education
- Females who are pre-menopausal and are pregnant.
- Use of antidepressants with large anticholinergic properties will be excluded. These include: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Novel measures of cognition and everyday function
No Practice Effects (NPE) cognitive battery Miami Computerized Functional Assessment Scale (CFAS) Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52. |
Novel measures of Cognitive and Everyday function
|
Active Comparator: Established measures of cognition and everyday function
Preclinical Alzheimer's Cognitive Composite (PACC) Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Functional Assessment Questionnaire (FAQ). Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period. Assessments will take place at baseline, week 12, and week 52. |
Established measures of Cognitive and Everyday Function
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Computerized Functional Assessment Scale (CFAS).
Time Frame: Baseline to Week 52; change in score will be assessed
|
Novel computerized measure of everyday function.
Testing format is a set of simulations (ATM use, Kiosk ticket purchase , Prescription refill , and Doctor's visit ).
We will construct a z score based on the "rate" measure which accounts for both speed and accuracy.
Higher scores suggest greater cognitive function while lower scores indicate greater cognitive impairment.
|
Baseline to Week 52; change in score will be assessed
|
No Practice Effect (NPE) Cognitive Battery.
Time Frame: Baseline to Week 52; change in score will be assessed
|
Novel measure of cognitive function.
Scores can be age-adjusted by decade.
The majority of the subtests ( including tests of Cognitive Control/Executive Processes, Working Memory,Speed of Processing,Verbal Fluency and Episodic Memory)are computerized or partially computerized.
All tests have three equivalent alternate forms.
We will construct a z-score averaged composite based on scores of the subtests at baseline.
Higher scores suggest greater cognitive function while lower scores indicate greater cognitive impairment.
|
Baseline to Week 52; change in score will be assessed
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Terry E. Goldberg, Ph.D., Columbia University Medical Center/ New York State Psychiatric Institute
Publications and helpful links
General Publications
- Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement (Amst). 2015 Mar 29;1(1):103-11. doi: 10.1016/j.dadm.2014.11.003. eCollection 2015 Mar.
- Bell SA, Cohen HR, Lee S, Kim H, Ciarleglio A, Andrews H, Rivera AM, Igwe K, Brickman AM, Devanand DP, Harvey PD, Schneider LS, Goldberg TE. Development of novel measures for Alzheimer's disease prevention trials (NoMAD). Contemp Clin Trials. 2021 Jul;106:106425. doi: 10.1016/j.cct.2021.106425. Epub 2021 Apr 30.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7672
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Xentria, Inc.Not yet recruiting
-
Incyte CorporationNot yet recruiting
-
Cerevel Therapeutics, LLCRecruitingHealthy ParticipantsUnited States
-
Novo Nordisk A/SRecruiting
-
H. Lundbeck A/SRecruiting
-
H. Lundbeck A/SRecruiting
-
ModernaTX, Inc.Recruiting
-
Shanghai Runshi Pharmaceutical Technology Co., LtdNot yet recruiting
-
Hospices Civils de LyonRecruitingHealthy ParticipantsFrance